PE20201495A1 - Compuesto de pirimidina como inhibidor de las janocinasas - Google Patents
Compuesto de pirimidina como inhibidor de las janocinasasInfo
- Publication number
- PE20201495A1 PE20201495A1 PE2020000414A PE2020000414A PE20201495A1 PE 20201495 A1 PE20201495 A1 PE 20201495A1 PE 2020000414 A PE2020000414 A PE 2020000414A PE 2020000414 A PE2020000414 A PE 2020000414A PE 20201495 A1 PE20201495 A1 PE 20201495A1
- Authority
- PE
- Peru
- Prior art keywords
- compound
- janocinases
- inhibitor
- pyrimidine compound
- amino
- Prior art date
Links
- -1 PYRIMIDINE COMPOUND Chemical class 0.000 title abstract 3
- 239000003112 inhibitor Substances 0.000 title 1
- 150000001875 compounds Chemical class 0.000 abstract 5
- OKKJLVBELUTLKV-UHFFFAOYSA-N methanol Natural products OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 abstract 2
- 208000023275 Autoimmune disease Diseases 0.000 abstract 1
- 208000027866 inflammatory disease Diseases 0.000 abstract 1
- 230000002757 inflammatory effect Effects 0.000 abstract 1
- 238000004519 manufacturing process Methods 0.000 abstract 1
- 239000008194 pharmaceutical composition Substances 0.000 abstract 1
- 239000000843 powder Substances 0.000 abstract 1
- 125000004527 pyrimidin-4-yl group Chemical group N1=CN=C(C=C1)* 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0014—Skin, i.e. galenical aspects of topical compositions
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D451/00—Heterocyclic compounds containing 8-azabicyclo [3.2.1] octane, 9-azabicyclo [3.3.1] nonane, or 3-oxa-9-azatricyclo [3.3.1.0<2,4>] nonane ring systems, e.g. tropane or granatane alkaloids, scopolamine; Cyclic acetals thereof
- C07D451/14—Heterocyclic compounds containing 8-azabicyclo [3.2.1] octane, 9-azabicyclo [3.3.1] nonane, or 3-oxa-9-azatricyclo [3.3.1.0<2,4>] nonane ring systems, e.g. tropane or granatane alkaloids, scopolamine; Cyclic acetals thereof containing 9-azabicyclo [3.3.1] nonane ring systems, e.g. granatane, 2-aza-adamantane; Cyclic acetals thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/06—Ointments; Bases therefor; Other semi-solid forms, e.g. creams, sticks, gels
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/14—Drugs for dermatological disorders for baldness or alopecia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D451/00—Heterocyclic compounds containing 8-azabicyclo [3.2.1] octane, 9-azabicyclo [3.3.1] nonane, or 3-oxa-9-azatricyclo [3.3.1.0<2,4>] nonane ring systems, e.g. tropane or granatane alkaloids, scopolamine; Cyclic acetals thereof
- C07D451/02—Heterocyclic compounds containing 8-azabicyclo [3.2.1] octane, 9-azabicyclo [3.3.1] nonane, or 3-oxa-9-azatricyclo [3.3.1.0<2,4>] nonane ring systems, e.g. tropane or granatane alkaloids, scopolamine; Cyclic acetals thereof containing not further condensed 8-azabicyclo [3.2.1] octane or 3-oxa-9-azatricyclo [3.3.1.0<2,4>] nonane ring systems, e.g. tropane; Cyclic acetals thereof
- C07D451/04—Heterocyclic compounds containing 8-azabicyclo [3.2.1] octane, 9-azabicyclo [3.3.1] nonane, or 3-oxa-9-azatricyclo [3.3.1.0<2,4>] nonane ring systems, e.g. tropane or granatane alkaloids, scopolamine; Cyclic acetals thereof containing not further condensed 8-azabicyclo [3.2.1] octane or 3-oxa-9-azatricyclo [3.3.1.0<2,4>] nonane ring systems, e.g. tropane; Cyclic acetals thereof with hetero atoms directly attached in position 3 of the 8-azabicyclo [3.2.1] octane or in position 7 of the 3-oxa-9-azatricyclo [3.3.1.0<2,4>] nonane ring system
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
- C07B2200/00—Indexing scheme relating to specific properties of organic compounds
- C07B2200/13—Crystalline forms, e.g. polymorphs
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Epidemiology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Immunology (AREA)
- Dermatology (AREA)
- Transplantation (AREA)
- Rheumatology (AREA)
- Pain & Pain Management (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Medicinal Preparation (AREA)
- Dental Preparations (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201762577852P | 2017-10-27 | 2017-10-27 | |
| PCT/US2018/057682 WO2019084383A1 (en) | 2017-10-27 | 2018-10-26 | PYRIMIDINE COMPOUNDS AS JAK KINASE INHIBITORS |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| PE20201495A1 true PE20201495A1 (es) | 2020-12-29 |
Family
ID=64277858
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| PE2020000414A PE20201495A1 (es) | 2017-10-27 | 2018-10-26 | Compuesto de pirimidina como inhibidor de las janocinasas |
Country Status (38)
Families Citing this family (12)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AU2018354370B2 (en) | 2017-10-27 | 2023-04-27 | Theravance Biopharma R&D Ip, Llc | Pyrimidine compound as JAK kinase inhibitor |
| MX2021006283A (es) * | 2018-11-30 | 2021-10-22 | Jiangsu Hansoh Pharmaceutical Group Co Ltd | Derivados heteroaromáticos para uso como regulador, método de preparación de los mismos y uso de los mismos. |
| AR118768A1 (es) | 2019-04-24 | 2021-10-27 | Theravance Biopharma R&D Ip Llc | Derivados de pirimidina como inhibidores de las cinasas jak |
| HRP20241053T1 (hr) * | 2019-04-24 | 2024-11-08 | Theravance Biopharma R&D Ip, Llc | Pirimidinski inhibitori jak, namijenjeni liječenju kožnih bolesti |
| KR102891680B1 (ko) * | 2020-07-28 | 2025-11-27 | 아큐티스 바이오테라퓨틱스, 인크. | Jak 저해제 및 라우레스-4를 함유하는 국소 제형 |
| BR112023003517A2 (pt) * | 2020-08-26 | 2023-05-09 | Nalo Therapeutics | Moduladores da proteína proto-oncogênica da família myc |
| WO2022076771A1 (en) * | 2020-10-08 | 2022-04-14 | Icahn School Of Medicine At Mount Sinai | Compositions for treatment alopecia areata, biomarkers for treatment success, and methods of use thereof |
| TW202311256A (zh) * | 2021-06-18 | 2023-03-16 | 美商基利科學股份有限公司 | 用於治療ｆｘｒ誘發之搔癢之ｉｌ－３１調節劑 |
| US20250051338A1 (en) | 2021-10-25 | 2025-02-13 | Kymera Therapeutics, Inc. | Tyk2 degraders and uses thereof |
| MX2024007437A (es) | 2021-12-15 | 2024-09-04 | Arcutis Biotherapeutics Inc | Formulaciones estables de shr0302. |
| CN114246938A (zh) * | 2022-01-25 | 2022-03-29 | 中山大学中山眼科中心 | Il-4在制备用于治疗视网膜变性疾病药物中的应用 |
| CN115487301B (zh) * | 2022-11-08 | 2023-07-07 | 四川大学华西医院 | Il-13抑制剂在制备延缓或治疗视网膜色素变性的药物中的用途 |
Family Cites Families (18)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4919934A (en) | 1989-03-02 | 1990-04-24 | Richardson-Vicks Inc. | Cosmetic sticks |
| US6660731B2 (en) | 2000-09-15 | 2003-12-09 | Vertex Pharmaceuticals Incorporated | Pyrazole compounds useful as protein kinase inhibitors |
| ATE346064T1 (de) | 2000-09-15 | 2006-12-15 | Vertex Pharma | Pyrazolverbindungen als protein-kinasehemmer |
| ATE354573T1 (de) | 2000-12-21 | 2007-03-15 | Vertex Pharma | ßPYRAZOLVERBINDUNGEN, DIE SICH ALS PROTEINKINASEINHIBITOREN EIGNENß |
| CA2588220A1 (en) | 2004-12-23 | 2006-06-29 | Pfizer Products Inc. | Heteroaromatic derivatives useful as anticancer agents |
| CA2629781A1 (en) | 2005-11-16 | 2007-05-24 | Vertex Pharmaceuticals Incorporated | Aminopyrimidines useful as kinase inhibitors |
| UY30444A1 (es) | 2006-06-30 | 2008-01-31 | Astrazeneca Ab | Derivados de pirimidina, procesos para su preparacinn, composiciones farmaccuticos y usos de los mismos. |
| CA2656290A1 (en) | 2006-07-05 | 2008-01-10 | Exelixis, Inc. | Methods of using igf1r and abl kinase modulators |
| WO2013092940A1 (en) | 2011-12-22 | 2013-06-27 | F. Hoffmann-La Roche Ag | 2, 4-diamine-pyrimidine derivative as serine/threonine kinase inhibitors |
| WO2015094803A1 (en) * | 2013-12-16 | 2015-06-25 | Calitor Sciences, Llc | Substituted heteroaryl compounds and methods of use |
| NO2721710T3 (OSRAM) | 2014-08-21 | 2018-03-31 | ||
| CN106687467A (zh) * | 2014-09-30 | 2017-05-17 | 韩美精密化学株式会社 | 高纯度（r）‑9‑[2‑（磷酰甲氧基）丙基]腺嘌呤的制备方法 |
| DK3303348T3 (da) | 2015-05-28 | 2019-11-11 | Theravance Biopharma R&D Ip Llc | Naphthyridinforbindelser som JAK-kinaseinhibitorer |
| US9938257B2 (en) | 2015-09-11 | 2018-04-10 | Calitor Sciences, Llc | Substituted heteroaryl compounds and methods of use |
| AU2017258186B2 (en) | 2016-04-28 | 2020-09-17 | Theravance Biopharma R&D Ip, Llc | Pyrimidine compounds as JAK kinase inhibitors |
| AU2018354370B2 (en) * | 2017-10-27 | 2023-04-27 | Theravance Biopharma R&D Ip, Llc | Pyrimidine compound as JAK kinase inhibitor |
| AR118768A1 (es) | 2019-04-24 | 2021-10-27 | Theravance Biopharma R&D Ip Llc | Derivados de pirimidina como inhibidores de las cinasas jak |
| HRP20241053T1 (hr) | 2019-04-24 | 2024-11-08 | Theravance Biopharma R&D Ip, Llc | Pirimidinski inhibitori jak, namijenjeni liječenju kožnih bolesti |
-
2018
- 2018-10-26 AU AU2018354370A patent/AU2018354370B2/en active Active
- 2018-10-26 MA MA49956A patent/MA49956B1/fr unknown
- 2018-10-26 TW TW107137865A patent/TWI789446B/zh active
- 2018-10-26 CA CA3074034A patent/CA3074034A1/en active Pending
- 2018-10-26 ES ES18801171T patent/ES2932526T3/es active Active
- 2018-10-26 PE PE2020000414A patent/PE20201495A1/es unknown
- 2018-10-26 BR BR112020008015-2A patent/BR112020008015A2/pt unknown
- 2018-10-26 WO PCT/US2018/057682 patent/WO2019084383A1/en not_active Ceased
- 2018-10-26 EA EA202091016A patent/EA202091016A1/ru unknown
- 2018-10-26 RS RS20220903A patent/RS63608B1/sr unknown
- 2018-10-26 SI SI201830770T patent/SI3672965T1/sl unknown
- 2018-10-26 PT PT188011712T patent/PT3672965T/pt unknown
- 2018-10-26 CU CU2020000053A patent/CU24671B1/es unknown
- 2018-10-26 UA UAA202003146A patent/UA125130C2/uk unknown
- 2018-10-26 MX MX2020004255A patent/MX2020004255A/es unknown
- 2018-10-26 IL IL274037A patent/IL274037B2/en unknown
- 2018-10-26 HU HUE18801171A patent/HUE060401T2/hu unknown
- 2018-10-26 LT LTEPPCT/US2018/057682T patent/LT3672965T/lt unknown
- 2018-10-26 DK DK18801171.2T patent/DK3672965T3/da active
- 2018-10-26 CR CR20200180A patent/CR20200180A/es unknown
- 2018-10-26 MD MDE20200681T patent/MD3672965T2/ro not_active IP Right Cessation
- 2018-10-26 SM SM20220409T patent/SMT202200409T1/it unknown
- 2018-10-26 CN CN201880068081.5A patent/CN111247142B/zh active Active
- 2018-10-26 US US16/171,693 patent/US10308646B2/en active Active
- 2018-10-26 KR KR1020207012597A patent/KR102613503B1/ko active Active
- 2018-10-26 HR HRP20221221TT patent/HRP20221221T1/hr unknown
- 2018-10-26 PL PL18801171.2T patent/PL3672965T3/pl unknown
- 2018-10-26 SG SG11202001706RA patent/SG11202001706RA/en unknown
- 2018-10-26 AR ARP180103131A patent/AR113803A1/es unknown
- 2018-10-26 EP EP18801171.2A patent/EP3672965B1/en active Active
- 2018-10-26 JP JP2020523324A patent/JP7218364B2/ja active Active
- 2018-10-26 GE GEAP201815340A patent/GEP20227344B/en unknown
-
2019
- 2019-04-22 US US16/390,175 patent/US10562894B2/en active Active
-
2020
- 2020-01-08 US US16/737,067 patent/US10774080B2/en active Active
- 2020-03-13 PH PH12020500528A patent/PH12020500528A1/en unknown
- 2020-03-16 ZA ZA2020/01641A patent/ZA202001641B/en unknown
- 2020-04-23 CL CL2020001090A patent/CL2020001090A1/es unknown
- 2020-04-24 NI NI202000032A patent/NI202000032A/es unknown
- 2020-04-27 EC ECSENADI202023795A patent/ECSP20023795A/es unknown
- 2020-05-06 DO DO2020000083A patent/DOP2020000083A/es unknown
- 2020-08-12 US US16/991,268 patent/US10988470B2/en active Active
-
2021
- 2021-03-30 US US17/301,243 patent/US11420965B2/en active Active
-
2022
- 2022-06-30 US US17/855,539 patent/US11814377B2/en active Active
-
2023
- 2023-10-03 US US18/480,442 patent/US12172994B2/en active Active
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| PE20201495A1 (es) | Compuesto de pirimidina como inhibidor de las janocinasas | |
| UY37927A (es) | Proceso para la preparación de 6-(2-hidroxi-2-metilpropoxi)-4-(6-(6-((6-metoxipiridin-3-il)metil)-3,6-diazabiciclo[3.1.1]heptan-3-il)piridin-3-il)pirazolo[1,5-a]piridina-3-carbonitrilo | |
| GEP20146125B (en) | Aminopyrimidines as syk inhibitors | |
| CL2011002115A1 (es) | Compuestos derivados de 5-fenil-1h-piridin-2-ona y 5-fenil-pirazin-2-ona, inhibidores de la tirosina-quinasa de bruton (btk); proceso de preparación de los compuestos, compuesto intermediario, composición farmacéutica y uso en el tratamiento de enfermedades inflamatorias y/o autoinmunes. | |
| EP4248988A3 (en) | Alkenyl substituted 2,5-piperazinediones and their use in compositions for delivering an agent to a subject or cell | |
| MX2015018048A (es) | Compuestos de benzofuranilo y benzoxazolilo sustituídos, y sus usos. | |
| PH12018501073A1 (en) | Eif4-a-inhibiting compounds and methods related thereto | |
| CL2012002265A1 (es) | Compuestos derivados de pirazol, potentes inhibidores de jak; composicion farmaceutica; combinacion farmaceutica; uso en el tratamiento de leucemia, tumores solidos, rechazo de trasplantes, enfermedades inmunitarias, entre otras. | |
| CL2017001426A1 (es) | Nuevos compuestos de 5-amino-6h-tiazolo[4,5-d]pirimidin-2,7-diona 3-sustituidos para el tratamiento y profilaxis de infecciones virales. | |
| CL2009001476A1 (es) | Compuestos derivados de 2,4-diamin-n2-fenil pirimidina sustituidos, mediadores de la inhibicion de igf-1r; composicion farmaceutica que comprende a dichos compuestos; y su uso en el tratamiento de enfermedades autoinmune, por trasplante, infecciosas o un trastorno proliferativo celular. | |
| WO2011117145A3 (en) | Pyrrolopyrazine kinase inhibitors | |
| BRPI0915084B8 (pt) | composto, e, composição farmacêutica | |
| UY32648A (es) | Nuevos derivados de pirimidina y su uso en el tratamiento de enfermedades | |
| NZ705040A (en) | Fused pyrimidines as inhibitors of p97 complex | |
| PH12015502737A1 (en) | Novel fused pyrimidine compound or salt thereof | |
| MX2012013274A (es) | Novedosos derivados de la pirimidina. | |
| MX2016006336A (es) | Compuestos pirazolopirimidina. | |
| PH12012501631A1 (en) | Pyrimidine derivatives and their use in the treatment of respiratory diseases such as copd | |
| TN2011000404A1 (en) | Fused pyrimidines | |
| PH12015501585A1 (en) | Manufacturing process for pyrimidine derivatives | |
| CL2015002635A1 (es) | Compuestos y composiciones para el tratamiento de enfermedades parasitarias | |
| MX2013010898A (es) | Novedoso derivados de la pirimidina. | |
| PH12012501630A1 (en) | Pyrimidine derivatives and their use in the treatment of respiratory diseases such as copd | |
| CL2015002520A1 (es) | Compuestos novedosos de pirimidina y piridina y su uso. | |
| MD20160053A2 (ro) | Derivaţi ai purinei 2,6-substituite şi utilizarea acestora în tratamentul tulburărilor proliferative |